Skip to content

Adjunctive esketamine and MECT for treatment-refractory bipolar depression

An exploratory study of adjunctive modified electroconvulsive therapy for treatment-resistant depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040082
Enrollment
Unknown
Registered
2020-11-20
Start date
2020-11-20
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment-refractory bipolar disorder

Interventions

Case series:esmketamine

Sponsors

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Be able to communicate and provide written consent; 2. Diagnosis of BD identified by treating psychiatrists and confirmed via a checklist of Diagnostic and Statistical Manual of Mental Disorders-4th edition (DSM-IV) criteria; TRBD defined as an insufficient therapeutic response to >=2 adequate antidepressants treatment trials during the current episode; 3. Male and female patients aged 18–65 years; 4. A total score of >= 17 on the 17-item Hamilton Rating Scale for Depression (HAMD-17) at screening; 5. Participants must have junior middle school and above years of schooling; 6. Han Chinese patients, right handedness.

Exclusion criteria

Exclusion criteria: (1) Other major psychiatric disorders that meet the DSM-IV diagnostic criteria include organic mental disorders, alcohol dependence, drug dependence/abuse, schizophrenia, etc; (2) Currently, there are serious and unstable somatic diseases such as diabetes, thyroid disease, hypertension, heart disease and narrow-angle glaucoma, etc; Wechsler intelligence test (WAIS-RC) full scale IQ (FIQ) total scores <= 80; (3) A history of neurological diseases such as epilepsy and dementia; (4) Subjects with metal in the body, such as pacemaker or brain electrode; (5) Previous history of anesthetics allergy; (6) Women who are at the stage of pre-pregnancy, pregnancy or lataction; (7) Contraindications to MRI or intolerant of MRI scanning environment, such as claustrophobia; (8) MECT treatment in the past three months, the doctor in charge thinks that MECT is not suitable for treatment.

Design outcomes

Primary

MeasureTime frame
Efficacy;

Secondary

MeasureTime frame
safety;Cognitive function;

Countries

China

Contacts

Public ContactXiong Huang

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital)

1195768576@qq.com+86 020-81268169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026